Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $66.5652W HIGH $144.35
Volume
93.36 K
Value Traded
10.48 M
Short % Float
7.53%
-10.35%Week
+5.49%1 Month
+34.29%3 Month
+30.31%6 Month
-56.12%5 Year
+3,521.33%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
713.53 M
EPS (TTM)
0.86
P/E Ratio
148.65
Ent. Value
748.93 M
Total Shares
5.60 M
Float Shares
5.36 M
Insiders
4.24%
Institutions
89.52%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MLAB Catalyst Timeline
Dated clinical, regulatory and corporate events for Mesa Laboratories, Inc.
Past FDA Catalysts and PDUFA Decisions
How MLAB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Mesa Laboratories, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every MLAB program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Capone Mark ChristopherDirector | Option | 2,784 6,213 held | $0.00 | 08/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MLAB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MLAB for Q2 2026. | ||||
MLAB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MLAB ranks across every disease it competes in
Competitive Position is a premium feature
See how MLAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMLAB News
MLAB▲ +0.9%today
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. has announced a quarterly dividend of $0.16 per share, payable on December 15, 2026, to shareholders of record by November 30, 2026. This decision highlights the company's ongoing commitment to shareholder returns. Mesa Labs operates globally, providing quality control solutions and life science tools across various regulated industries.
Read more →MLAB▼ -14.5%on this news
Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results
Mesa Laboratories reported a 2.6% revenue increase in Q4 2026, with a notable 87% rise in operating income. The company faced challenges in its Biopharmaceutical Development division, which saw a significant revenue decline due to shipping delays and execution issues. Despite these setbacks, Mesa's overall financial health improved, highlighted by a reduction in debt and a strong performance in its Sterilization and Disinfection Control division.
Read more →MLABMesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
Mesa Laboratories, Inc. will release its financial results for the fourth quarter and full fiscal year on May 27, 2026. The results will cover the period ending March 31, 2026, and will be made available at 6:00 A.M. ET. Mesa is recognized for its contributions to life science tools and quality control solutions.
Read more →MLABMESA LABS DECLARES QUARTERLY DIVIDEND - April 2, 2026
Mesa Laboratories, Inc. has announced a quarterly dividend of $0.16 per share, payable on June 15, 2026. Shareholders of record by May 29, 2026, will receive this dividend. The company is recognized for its contributions to life science tools and quality control solutions across various regulated industries.
Read more →MLABMesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
LAKEWOOD, Colo., March 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens will step down as Pre
Read more →MLAB▲ +8.7%on this news
Mesa Labs Announces Third Quarter Results
Mesa Laboratories reported a 3.6% organic revenue growth for the third quarter of FY26, driven by strong performance in its Biopharmaceutical Development division. Profitability improved significantly, with a 26.2% margin. However, the Clinical Genomics division faced challenges, particularly in China, leading to a revenue decline. The company remains optimistic about future growth as market conditions stabilize.
Read more →MLABMesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens, President and CEO, and John Sakys, CFO will prese
Read more →MLABMesa Laboratories, Inc. to Announce Third Quarter Results on February 3, 2026
LAKEWOOD, Colo., Dec. 03, 2025 (GLOBE NEWSWIRE) -- - Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern Time (ET) on Tuesday, February 3, 2026. About Mesa Laborator
Read more →MLABMesa Laboratories, Inc. to Participate in Upcoming Investor Conferences
Mesa Laboratories, Inc. has announced its participation in several upcoming investor conferences, including the Raymond James Napa Valley Small Cap Symposium and the Jefferies London Healthcare Conference. CEO Gary Owens and CFO John Sakys will represent the company at these events. The conferences provide a platform for Mesa to engage with investors and share insights about its operations.
Read more →MLABMesa Labs Announces Second Quarter Results
Mesa Laboratories reported its second quarter results for FY26, showing a 5.0% increase in organic revenue compared to the previous year. The company experienced strong growth in its Biopharmaceutical Development and Calibration Solutions divisions, although it faced challenges in Clinical Genomics, particularly in China. Despite a decrease in net income, profitability metrics remained robust, and the company anticipates further revenue growth in the upcoming quarter.
Read more →MLABMesa Laboratories, Inc. to Announce Second Quarter Results on November 6, 2025
Mesa Laboratories, Inc. will announce its financial results for the second quarter of fiscal year 2026 on November 6, 2025. The announcement will follow market close, providing insights into the company's performance. Mesa is recognized for its contributions to the pharmaceutical and healthcare industries through its life science tools and quality control solutions.
Read more →MLABMesa Laboratories Executes Previously-Announced Strategic Financing Plan
Mesa Laboratories has successfully executed its financial strategy by repaying $97.5 million in convertible senior notes due August 2025. The company utilized $97.0 million from its credit agreement to settle these notes. Mesa's CFO highlighted the strategic steps taken to optimize capital structure and reduce shareholder dilution while maintaining a strong cash flow to manage debt obligations.
Read more →MLAB▼ -24.9%on this news
Mesa Labs Announces First Quarter Results
LAKEWOOD, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“1Q26”) ended June 30, 2025
Read more →MLABMesa Laboratories, Inc. to Announce First Quarter Results on August 5, 2025
LAKEWOOD, Colo., July 02, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the first quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern time on Tuesday, August 5, 2025. About Mesa Laboratories, Inc.
Read more →MLAB▼ -8.9%on this news
Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2025 Results
Mesa Laboratories, Inc. reported its fourth quarter and full fiscal year 2025 results, highlighting a 5.0% core organic revenue growth for the year. The company achieved strong bookings growth across all divisions, although profitability was affected by increased performance-based compensation. Notably, the Clinical Genomics division experienced a decline in annual core organic revenues. The company also successfully integrated GKE and launched new products.
Read more →About Mesa Laboratories, Inc.
Headquarters12100 W 6TH AVE, LAKEWOOD, CO, 80228
BIOPHARMAWATCH ELITE PLUS
Trade the next MLAB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime